Metastatic Prostate Cancer – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Metastatic Prostate Cancer – Drugs In Development, 2024 report and make more profitable business decisions.
Metastatic prostate cancer occurs when cancerous cells from the prostate gland spread via the bloodstream or lymphatic system to distant sites, especially the bones (such as the spine, pelvis, or hips), lymph nodes, liver, lungs, and other organs. It’s considered an advanced stage of prostate cancer and can present challenges in treatment and management. Metastatic prostate cancer can cause various symptoms depending on the organs affected, including bone pain (often in the spine, hips, or ribs), urinary problems, erectile dysfunction, weakness or numbness in the legs or feet, weight loss, and fatigue.
The Metastatic Prostate Cancer drugs in development market research report provide comprehensive information on the therapeutics under development for Metastatic Prostate Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Prostate Cancer and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Metastatic Prostate Cancer | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 70 molecules, with 62 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Metastatic Prostate Cancer therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Metastatic Prostate Cancer pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Metastatic Prostate Cancer treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
Abion IncActinium Pharmaceuticals Inc
Advanced Accelerator Applications SA
Alligator Bioscience AB
Alphamab Oncology
Antev Ltd
Artelo Biosciences Inc
Beth Israel Deaconess Medical Center
Bio-Thera Solutions Ltd
BioNTech SE
Bristol-Myers Squibb Co
Camurus AB
Cancer Targeted Technology LLC
Crystal Nucleus Biomedical Technology (Nanjing) Co Ltd
CSPC Pharmaceutical Group Ltd
CureMeta LLC
EpimAb Biotherapeutics Inc
Exelixis Inc
For-Robin Inc
Foresee Pharmaceuticals Co Ltd
Fusion Pharmaceuticals Inc
Glycomantra Inc
GlyTherix Ltd
GSK plc
Huabo Biopharm (Shanghai) Co Ltd
Immune Pharmaceuticals Inc
Immunogenesis Inc
Immunova Therapeutics Inc
Kintor Pharmaceutical Ltd
Komipharm International Co Ltd
Kyorin University
Livzon Pharmaceutical Group Co Ltd
Lotus Pharmaceutical Co Ltd
Luye Pharma Group Ltd
Memorial Sloan Kettering Cancer Center
MetasTx LLC
Nanjing Medical University Hospital
National Cancer Institute US
NeoTX Therapeutics Ltd
Novartis AG
Oncotelic Therapeutics Inc
Oncternal Therapeutics
Oneness Biotech Co Ltd
Orion Corp
Pharmadrug Inc
Praesidia Biotherapeutics Inc
Precision Molecular Inc
QSAM Therapeutics Inc
Ratio Therapeutics Inc
Roswell Park Cancer Institute
Samyang Biopharmaceuticals Corp
Sathgen Biotech
Shanghai Yuyao Biotechnology Ltd
Shanxi Kangbao Biological Product Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sihuan Pharmaceutical Holdings Group Ltd
Spanish National Research Council
Spexis AG
SynDevRx Inc
Telix Pharmaceuticals Ltd
Theratechnologies Inc
University of East Anglia
Wuxi Biocity Biopharma Co Ltd
Xennials Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Metastatic Prostate Cancer reports